Introduction
============

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death in the world [@B1]. Although GC mostly occurs in the 50-70 age groups and the overall incidence of GC has declined in last decade, the incidence rate in younger patients has increased [@B2], [@B3]. Compared to the older age group, the clinicopathological features and prognosis of young GC patients remain controversial. Some studies have revealed that the prognosis of GC is worse in younger patients due to delayed diagnosis or more advanced stage [@B4]-[@B6]. However, other studies state that the prognosis in the young patients is comparable to the older patients [@B7]-[@B9], or even better[@B10], [@B11]. The controversy findings may result from many reasons, including sample size, ethnicity, and different definitions of young age group. Most literatures defined young age as below 40 or 45 years[@B5]-[@B7], [@B9], [@B12]-[@B19], while others used 30, 50, 60 or even 70 [@B4], [@B8], [@B10], [@B11], [@B20]-[@B23]. The difference of cut-off value for ages may lead to different outcomes of analysis. Besides, in clinical practice, we found that the proportion of extremely young patients (20-30 years old) was increasing, and prognosis of this age group was poor. To investigate the association between age and prognosis, we reviewed the epidemiologic and clinicopathological characteristics of GC patients based on Surveillance, Epidemiology, and End Results (SEER) population-based data.

Methods
=======

Database
--------

The SEER database is the largest publicly available cancer dataset. It is a population-based cancer registry across several disparate geographic regions. The SEER research data include cancer incidence and prevalence as well as demographic information tabulated by age, sex, race / ethnicity, year of diagnosis and Tumor-Node-Metastasis (TNM) stage. The exact dataset we used for this analysis was SEER Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) Research Data (1973-2014), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, based on the November 2016 submission.

Another cohort from the Sun Yat-sen University Cancer Center (SYSUCC) was used as external validation data. It included all the gastric adenocarcinoma cancer patients who received therapy and had full record of follow-up in SYSUCC during 2000 and 2013 (Supplementary table [1](#SM0){ref-type="supplementary-material"}). The study protocol for the Chinese cohort was approved by the independent Ethics Committees at SYSUCC.

Outcome variables
-----------------

Variable definitions information on age at diagnosis, sex, year of diagnosis, race/ethnicity, primary site, tumor grade and differentiation, histology, lymph node involvement, AJCC 7^th^ TNM stage, insurance status and overall survival were coded and available in SEER database.

The primary site was defined by the following International Classification of Diseases for Oncology (ICD-O-2) codes: C16.0-C16.9. Cardia, (C16.0), fundus (C16.1), body (C16.2), antrum (C16.3), pylorus (C16.4), lesser curvature (C16.5), greater curvature (C16.6), overlapping lesion (C16.7) and stomach, NOS (C16.9).

Grade and differentiated was defined by the following ICD-O-2 codes; well differentiated (Code 1), moderate differentiated (Code 2), poorly differentiated (Code 3) and undifferentiated (Code 4).

Histological types were defined by the following ICD-O-3 codes: 8140 to 8147, 8210 to 8211, 8220 to 8221, and 8260 to 8263 for adenocarcinoma, 8480 and 8481 for mucinous adenocarcinoma, and 8490 for Signet ring cell carcinoma.

For the Race/Ethnicity, we reclassified the patients into 5 groups: "Caucasian", "African American", "Asian", "Others" and "Unknown".

Patient Population
------------------

The study population was based on the SEER cancer registry. We restricted eligibility to patients with gastric adenocarcinoma (including mucinous adenocarcinoma and signet ring cell carcinoma) from 1973 to 2014 with an age≥18. We excluded cases without follow-up records (survival time code of 0 months).

Statistical Methods
-------------------

The patients\' demographic and tumor characteristics were summarized with descriptive statistics. Comparisons of categorical variables were performed using the Chi square test, and continuous variables were compared using Student\'s t test. The primary endpoint of this study was 5-year cause specific survival (CSS), which was calculated from the date of diagnosis to the date of cancer specific death. Deaths attributed to gastric cancer were treated as events and deaths from other causes were treated as censored observations. Survival function estimation and comparison among different variables were performed using Kaplan-Meier estimates and the log-rank test. The independence of the prognostic factors was adjusted for other known factors including age at diagnosis and tumor stage. All of statistical analyses were performed using the Intercooled Stata 13.0 (Stata Corporation, College Station, TX). Statistical significance was set at two-sided P \< 0.05.

Informed consent and Protection of Human Subjects
-------------------------------------------------

This study with SEER data was deemed exempt from institutional review board approval by Sun Yat-sen University Cancer Center and informed consent was waived. The study protocol for the Chinese cohort was approved by the independent Ethics Committees at SYSUCC.

Results
=======

Cut-off points of age groups
----------------------------

We identified 79,505 GC patients diagnosed between 1973 and 2014 with an age≥18. The median age of the whole population was 68 years old (mean±SD: 66.43±13.74). We divided the patients into 11 age groups (every 5 years of age). Since the number of patients younger than 30 was small, we combined these patients into one group. If the median overall survival between two adjacent groups were significantly different, the youngest age of the latter group was set as the cut-off value (Table [1](#T1){ref-type="table"}). Based on the cut-off points, all the patients were divided into 4 groups as follows: young age patients: 18-34 years; middle-age patients: 35-64 years; elderly patients: 65-74 years; extremely elderly patients: \>74 years. Young age patients accounted for 1.72% (1369/79505) of all GC patients.

Epidemiologic and clinicopathological characteristics
-----------------------------------------------------

General epidemiologic and clinicopathological characteristics among different age groups were summarized in Table [2](#T2){ref-type="table"}. The proportion of young age patients had increased faster than the other 3 groups during the last decade. The proportion of female was significantly higher in young age group, compared to the middle-age and the elderly (46.8%, 31.6% and 32.4%, respectively. P\<0.001). The ethnic composition and location of lesions were different between young age group and the other 3 groups (All P\<0.001). The diffuse type GC was much more common in the young age group (47.6%) than in the other 3 age groups (26.8%, 17.6%, 12.8%, respectively, all P \<0.001). Besides, poorly differentiated tumors were remarkably more common in the young age group (66.9%), and signet-ring cell carcinoma was more frequently seen in the young age patients (40.8%). Moreover, less patients in the young age group received surgery (45.4%) than the middle-age and the elderly groups (P\<0.001), which was similar with the extremely elderly group. More young patients were diagnosed with distant metastasis (28.1%) than the other 3 groups.

Survival analysis
-----------------

The median CSS of the young age group was 12 months, which was significantly lower than the middle-age and the elderly groups (15 and 16 months, respectively, both P\<0.001). The median overall survival between young age group and extremely elderly group was comparable (12 months vs. 13 months, P=0.153) (Fig [1](#F1){ref-type="fig"}). To explore the prognostic factor for young age GC patients, we carried out the univariate and multivariate analysis in young GC group (Table [3](#T3){ref-type="table"}). There were 952 deaths (69.54%) in this group with a 5-year CSS of 14.61% (95%CI: 12.80%-16.54%).

Variables showing a trend for association with survival (P \< 0.05) were selected in the cox proportional hazards model. Tumor location, ethnicity, tumor size (≥5cm), surgery and TNM stage were identified as independent prognostic factors in young GC patients by both univariate and multivariate analysis.

Validation using GC patients from SYSUCC
----------------------------------------

We found that patients younger than 35 years old still had the worst prognosis among the four age groups (Figure [2](#F2){ref-type="fig"}). The median survival for these 4 groups patients were as follow: 25 months for patients younger than 35 years old, 57 months for patients who were 35-64 years, 43 months for patients who were 65-74 years and 38 months for patients \>74 years old, P=0.0003.

Discussion
==========

The prognosis of GC in different age groups is still controversial. This may result from different definitions of young age. Most literatures defined young age as below 40 or 45 years[@B5]-[@B7], [@B9], [@B12]-[@B19], while others used 30, 50, 60 or even 70 [@B4], [@B8], [@B10], [@B11], [@B20]-[@B23]. Some studies simply used median age as the cutoff value to analyze the prognosis of age in GC patients [@B24]-[@B27]. Most of the studies come to the conclusion that young patients had a better prognosis than elderly patients with the possible explanation that young patients had better performance status and better tolerance to therapy, while elderly patients might have more complication and could not stand effective therapy [@B10]. In our clinical practice, we realized that young patients should be treated as two distinct types, pretty young patients who actually had worse prognosis than older patients and middle-age patients who had better prognosis. How can we figure out the young patients who have poor prognosis? In our study, we compared the survival of different groups GC patients according to their ages with an interval of 5 years. By combining patients with similar prognosis, we figured out 3 cutoff values, 35 years old, 65 years old and 75 years old. By this, we divided patients into 4 groups: young age patients: 18-34 years; middle-age patients: 35-64 years; elderly patients: 65-74 years; extremely elderly patients: \>74 years. Young patients had the worst prognosis, while the elderly group had the best prognosis. The median survivals for these two groups were 12months and 16months, respectively, P\<0.001. The poor prognosis for young patients remained valid in the SYSUCC database.

During the last few decades, the incidence of GC has declined in most countries. However, there is a rising trend in the incidence of GC in young age patients [@B2]. Our study also showed that the proportion of young GC patients had increased in the last 4 decades. It has been suggested that GC in young patients has different clinical features and tumor behavior from older gastric cancer. Most common reported features by literatures included female dominance, location in upper third area, undifferentiated and diffuse histologic types, advanced stage at diagnosis [@B5]-[@B7], [@B9], [@B10], [@B15], [@B23], [@B28], [@B29]. In our study, the percentage of female patients in the young patient subgroup was higher than that in other age groups. The male-to-female ratio in the young age group was 1.14, in contrast to 2.16 in middle age group and 2.08 in elderly group. The reason for higher proportion of female in the young age group remains controversial. Sex hormone especially estrogen has been suggested to play a role in pathogenesis of GC [@B14], [@B30]-[@B33]. Some studies reported the protective effect of estrogen in GC [@B30], [@B32], [@B33], while others claimed the opposite [@B14], [@B31]. Chung et.al suggested that the excessive exposure of estrogen without the counter effect of progesterone may increase the risk of GC [@B14]. Further studies are needed to clarify the underlying mechanism of female dominance in young age GC patients.

Regarding histologic classifications, previous studies have showed poor-differentiated or undifferentiated and diffuse-type gastric cancer predominated in young age patients [@B7], [@B9], [@B14], [@B15], [@B23], [@B34]. Our study also showed a higher proportion of diffuse type and poor differentiated gastric cancer in the young age group. Previous studies indicated that intestinal-type and well differentiated GC originates from intestinal metaplasia or atrophic gastritis, which is associated with infection by *Helicobacter pylori*. This progression from infection of *H.pylori* to pre-malignant stage and finally malignant tumor may take many years [@B35]-[@B37]. However, the diffuse-type adenocarcinoma or poor-differentiated gastric cancer may develop without passing all these stages. Young age patients have fewer years to pass through these stages, which may partially explain why diffuse-type and poor-differentiated is more common in the young age group. Moreover, it has been reported that diffuse type GC is associated with E-cadherin deregulation upon genetic alterations [@B38], and E-cadherin gene (CDH1) mutations are more common in young age GC [@B39]. According to the definition of hereditary diffuse gastric cancer, diffuse gastric cancer patients who are younger than 40 years old have met the criteria [@B40]. Hence the genetic factors may play an important role in the development of GC in young age patients.

To explore the factors that contribute to the worse survival in pretty young GC patients, we carried out the univariate and multivariate analysis. We found that location of tumor, ethnicity, tumor size, surgery and TNM stage were independent risk factors in young age patients. Previous studies have suggested various clinicopathological factors, including tumor location, tumor size, depth of invasion, lymphovascular invasion, peritoneal metastasis, distant metastasis, curative resection, CEA and CA125 level, and TNM stage [@B5]-[@B7], [@B10], [@B14], [@B17]-[@B19], [@B23], [@B34], [@B41]. Curative resection was the most common risk factor seen in these studies. Several studies found that the prognosis of young age patients after curative surgery was comparable or better than the old age patients [@B5], [@B23], [@B41], [@B42], and prognosis of advanced stages was worst in young age patients than the old age patients [@B29], [@B43]. However, few young age patients present with alarm symptoms and they do not receive regular screen by gastroscopy. More patients in young age group were diagnosed at stage IV and lost the chance for curative resection. Considering genetic factors may play a role in development of early gastric cancer, it is reasonable to offer earlier screening to young people with family history. Further studies are warranted to figure out the high risk factor for gastric cancer and based on these to design the screen strategy in high risk young people. It is also important to find out more effective screen methods, such as liquid biopsy or superfine gastroscopy.

There were some limitations to this study. Firstly, it was a retrospective study. Secondly, as this study overlapped long time frame and AJCC staging system for gastric cancer changed, the current study couldn\'t reflect the stages and clinical practice of gastric cancer in previous years. Thirdly, the SEER database does not include data on signs and symptoms, family history, level of tumor markers, chemotherapy, and other factors that might affect prognosis. Further studies are needed to elucidate the mechanism for poor prognosis of young age patients.

Conclusion
==========

This study demonstrated that gastric cancer patients \<35 years old had a poor prognosis. Location of tumor, ethnicity, tumor size, surgery and TNM stage were independent risk factors on prognosis for young patients. Early detection of gastric cancer is very important in all patients but in young patients it is of paramount importance.
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###### 

Survival analysis among different age groups

  Age group   Age             Number (%)      Median CSS (Months)   5-year CSS rate (%)   95% CI (%)    P value
  ----------- --------------- --------------- --------------------- --------------------- ------------- ---------
  Group 1     \<30            499 (0.63)      14                    21.53                 17.55-25.79   0.0872
  30-34       870 (1.09)      15              25.46                 22.31-28.71           0.0166        
  Group 2     35-39           1539 (1.94)     17                    30.56                 28.09-33.06   0.3868
  40-44       2623 (3.30)     17              28.68                 26.80-30.58           0.3833        
  45-49       4097 (5.15)     18              29.87                 28.37-31.39           0.6340        
  50-54       6065 (7.63)     18              28.75                 27.51-30.01           0.1731        
  55-59       7821 (9.84)     19              29.49                 28.39-30.61           0.2634        
  60-64       9470 (11.91)    19              29.27                 28.26-30.29           0.0086        
  Group 3     65-69           10887 (13.70)   19                    31.75                 30.80-32.72   0.2732
  70-74       11212 (14.10)   20              31.37                 30.43-32.32           0.0071        
  Group 4     75+             24422 (30.72)   16                    27.34                 26.70-27.98   

CSS: Cause specific survival, CI: Confidential Interval.

###### 

Comparison of clinic-pathologic features among different age groups

  -------------------------------------------------------------------------------------------------
                            \<35 (%)\     35-64 (%)\      65-74 (%)\      \>74 (%)\       P value
                            (N=1369)      (N=31615)       (N=22099)       (N=24422)       
  ------------------------- ------------- --------------- --------------- --------------- ---------
  Sex                                                                                     

  Male                      728 (53.18)   21618 (68.38)   14935 (67.58)   13169 (53.92)   

  Female                    641 (46.82)   9997 (31.62)    7164 (32.42)    11253 (46.08)   \<0.001

  Year                                                                                    

  1973-1983                 115 (8.40)    4295 (13.59)    3292 (14.90)    3328 (13.63)    

  1984-1993                 175 (12.78)   4305 (13.62)    3826 (13.71)    3752 (15.36)    

  1994-2003                 399 (29.15)   8145 (25.76)    6118 (27.68)    7208 (29.51)    

  2004-2014                 680 (49.67)   14870 (47.03)   8863 (40.11)    10134 (41.50)   \<0.001

  Lauren                                                                                  

  Diffuse                   652 (47.63)   8473 (26.80)    3883 (17.57)    3138 (12.85)    

  Intestinal                668 (48.79)   21927 (69.36)   17330 (78.42)   20469 (83.81)   

  Unknown                   49 (3.58)     1215 (3.84)     886 (4.01)      815 (3.34)      \<0.001

  Grade                                                                                   

  Well                      31 (2.26)     1162 (3.68)     1117 (5.05)     1376 (5.63)     

  Moderate                  123 (8.98)    6233 (19.72)    5363 (24.27)    6724 (27.53)    

  Poorly                    916 (66.91)   17728 (56.07)   11414 (51.65)   11202 (45.87)   

  Undifferentiated          44 (3.21)     779 (2.46)      493 (2.23)      426 (1.74)      

  Unknown                   255 (18.63)   5713 (18.07)    3712 (16.80)    4694 (19.22)    \<0.001

  Ethnicity                                                                               

  Caucasian                 888 (64.86)   22027 (69.67)   15654 (70.84)   17795 (72.86)   

  African-American          180 (13.15)   4306 (13.62)    2592 (11.73)    2404 (9.84)     

  Asian                     225 (16.44)   4399 (13.91)    3353 (15.17)    3849 (15.76)    

  Others                    76 (5.55)     883 (2.79)      500 (2.26)      374 (1.53)      \<0.001

  Primary site                                                                            

  Cardia                    295 (21.55)   10469 (33.11)   6611 (29.92)    5228 (21.41)    

  Fundus                    43 (3.14)     1065 (3.37)     795 (3.60)      949 (3.89)      

  Body                      133 (9.72)    2165 (6.85)     1598 (7.23)     2019 (8.27)     

  Antrum                    229 (16.73)   5556 (17.57)    4471 (20.23)    6026 (24.67)    

  Pylorus                   46 (3.36)     987 (3.12)      764 (3.46)      982 (4.02)      

  Lesser curvature          121 (8.84)    2894 (9.15)     2225 (10.07)    2537 (10.39)    

  Greater curvature         61 (4.46)     1234 (3.90)     906 (4.10)      1014 (4.15)     

  Overlapping               153 (11.18)   2629 (8.32)     1728 (7.82)     1923 (7.87)     

  NOS                       288 (21.04)   4616 (14.60)    3001 (13.58)    3744 (15.33)    \<0.001

  Surgery                                                                                 

  Yes                       720 (52.60)   19799 (62.63)   14516 (65.69)   13149 (53.84)   

  No                        621 (45.36)   11245 (35.57)   7112 (32.18)    10642 (43.58)   

  Unknown                   28 (2.05)     571 (1.81)      471 (2.13)      631 (2.58)      \<0.001

  Histology                                                                               

  Adenocarcinoma            786 (57.41)   23721 (75.03)   18372 (83.13)   21403 (87.64)   

  Signet Ring cell          558 (40.76)   7169 (22.68)    3208 (14.52)    2548 (10.43)    

  Mucinous adenocarcinoma   25 (1.83)     725 (2.29)      519 (2.35)      471 (1.93)      \<0.001

  Tumor size (mm)                                                                         

  Median                    50            45              40              40              

  Mean±SD                   158.0±300.3   91.6±197.1      71.9±156.7      65.2±138.8      \<0.001

  AJCC 7^th^ T stage                                                                      

  T1                        119 (8.69)    3011 (9.52)     2194 (9.93)     2951 (12.08)    

  T2                        42 (3.07)     1225 (3.87)     863 (3.91)      967 (3.96)      

  T3                        129 (9.42)    3545 (11.21)    2160 (9.77)     2020 (8.27)     

  T4                        222 (16.22)   4404 (13.93)    2233 (10.10)    1987 (8.14)     

  Tx                        857 (62.60)   19430 (61.46)   14649 (66.29)   16497 (67.55)   \<0.001

  AJCC 7^th^ N stage                                                                      

  N0                        216 (15.78)   5273 (16.68)    3629 (16.42)    4851 (19.86)    

  N1                        243 (17.75)   5511 (17.43)    3114 (14.09)    2773 (11.35)    

  N2                        64 (4.67)     1659 (5.25)     845 (3.82)      708 (2.90)      

  N3                        30 (2.19)     666 (2.11)      363 (1.64)      254 (1.04)      

  Nx                        816 (59.61)   18506 (58.54)   14148 (64.02)   15836 (64.84)   \<0.001

  AJCC 7^th^ M stage                                                                      

  M0                        276 (20.16)   9010 (28.50)    6184 (27.98)    7512 (30.76)    

  M1                        385 (28.12)   5452 (17.24)    2403 (10.87)    1955 (8.01)     

  MX                        708 (51.72)   17153 (54.26)   13512 (61.14)   14955 (61.24)   \<0.001

  AJCC 7^th^ TNM stage                                                                    

  IA                        36 (2.63)     1290 (4.08)     1132 (5.12)     1364 (5.59)     

  IB                        15 (1.10)     755 (2.39)      612 (2.77)      730 (2.99)      

  IIA                       21 (1.53)     844 (2.67)      660 (2.99)      761 (3.12)      

  IIB                       38 (2.78)     1531 (4.84)     999 (4.52)      987 (4.04)      

  IIIA                      51 (3.73)     1490 (4.71)     934 (4.23)      744 (3.05)      

  IIIB                      40 (2.92)     1207 (3.82)     629 (2.85)      543 (2.22)      

  IIIC                      28 (2.05)     710 (2.25)      434 (1.96)      320 (1.31)      

  IV                        385 (28.12)   5452 (17.24)    2403 (10.87)    1955 (8.01)     

  Unknown                   755 (55.15)   18336 (58.00)   14296 (64.69)   17018 (69.69)   \<0.001
  -------------------------------------------------------------------------------------------------

NOS: Not otherwise specified; SD: Standard Deviation; AJCC: The American Joint Committee on Cancer; TNM: Tumor Node Metastasis

###### 

Survival analysis for young patients with gastric cancer

                              Univariate analysis   Multivariate analysis                                        
  --------------------------- --------------------- ----------------------- --------- ----------- -------------- ---------
  Sex                                                                                 \--                        
  Male                        14                    22.09%                            \--                        
  Female                      16                    26.45%                  0.0667    \--                        
  Location                                                                                                       
  Cardia                      13                    16.26%                            Reference                  
  Fundus                      10                    14.64%                            0.989       0.887-1.103    0.845
  Body                        16                    28.66%                            0.986       0.912-1.067    0.735
  Antrum                      22                    35.72%                            0.974       0.918-1.032    0.373
  Pylorus                     22                    32.83%                            1.042       0.930-1.167    0.478
  Lesser curvature            26                    33.57%                            0.870       0.806-0.939    \<0.001
  Greater curvature           17                    31.61%                            1.060       0.958-1.173    0.261
  Overlapping                 10                    10.38%                            1.094       1.013-1.180    0.021
  NOS                         12                    21.68%                  \<0.001   1.056       0.977-1.142    0.171
  Race/Ethnicity                                                                                                 
  Caucasian                   14                    22.57%                            Reference                  
  African-American            11                    20.29%                            0.987       0.928-1.050    0.684
  Asian                       22                    30.15%                            0.805       0.760-0.853    \<0.001
  Others                      13                    32.33%                  0.0005    0.931       0.807-1.074    0.327
  Tumor size                                                                                                     
  \<5cm                       40                    38.47%                            Reference                  
  \>=5cm                      15                    18.27%                  \<0.001   1.124       1.078-1.172    \<0.001
  Lauren                                                                              \--                        
  Diffuse                     15                    23.94%                            \--                        
  Intestinal                  14                    23.99%                  0.5443    \--                        
  Histology subgroup                                                                  \--                        
  Adenocarcinoma              15                    24.21%                            \--                        
  Signet Ring cell            15                    23.48%                            \--                        
  Mucinous adenocarcinoma     13                    34.89%                  0.9155    \--                        
  Grade                                                                               \--                        
  Well differentiated         21                    31.52%                            \--                        
  Moderately differentiated   17                    26.35%                            \--                        
  Poorly differentiated       15                    23.88%                            \--                        
  Undifferentiated            11                    16.35%                  0.0951    \--                        
  Surgery                                                                                                        
  Yes                         25                    34.50%                            Reference                  
  No                          9                     11.51%                  \<0.001   2.082       1.970-2.200    \<0.001
  AJCC 7^th^ TNM stage                                                                                           
  IA                          NR                    93.15%                            Reference                  
  IB                          NR                    60%                               2.007       1.744-2.311    \<0.001
  IIA                         80                    54.62%                            2.733       2.402-3.109    \<0.001
  IIB                         60                    50.51%                            4.325       3.845-4.864    \<0.001
  IIIA                        27                    21.50                             5.837       5.191-6.564    \<0.001
  IIIB                        27                    40.19%                            7.311       6.481-8.247    \<0.001
  IIIC                        19                    31.28%                            10.190      8.971-11.574   \<0.001
  IV                          9                     4.97%                             10.640      9.473-11.951   \<0.001

NOS: Not otherwise specified; CSS: Cause Specific Survival; AJCC: The American Joint Committee on Cancer; TNM: Tumor Node Metastasis
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